J. Lind

发表

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

C. V. van Kuijk, D. de Ruysscher, E. Smit, 2010, European Radiology.

Cardiac assessment of patients with late stage Duchenne muscular dystrophy

J. Zijlstra, L. Aarts, P. Wijkstra, 2009, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.

E. Smit, S. Senan, F. Lagerwaard, 2009, International Journal of Radiation Oncology, Biology, Physics.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

E. Smit, P. Postmus, J. Lind, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.

E. Giovannetti, C. Tibaldi, E. Smit, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Management of advanced non-small cell lung cancer: moving towards a more personalised approach

J. Lind, 2012 .

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

E. Giovannetti, G. Peters, H. Groen, 2010, Clinical Cancer Research.

Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer

E. Smit, J. Lind, 2009, Therapeutic advances in medical oncology.

VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

E. Smit, A. Dingemans, H. Roder, 2012, British Journal of Cancer.

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.

E. Smit, S. Senan, J. Lind, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time for reappraisal of extracranial treatment options?

E. Smit, S. Senan, F. Lagerwaard, 2011, Cancer.

CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

E. Smit, H. Verheul, V. V. van Hinsbergh, 2009, British Journal of Cancer.

CD133 CIRCULATING HEMATOPOIETIC PROGENITOR CELLS PREDICT FOR RESPONSE TO SORAFENIB PLUS ERLOTINIB IN NON-SMALL CELL LUNG CANCER PATIENTS

H. Verheul, H. Broxterman, J. Lind, 2010 .

University of Groningen Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients Corstjens,

J. Ligtenberg, J. Zijlstra, J. Tulleken, 2015 .

Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients

Jaap E Tulleken, J. Ligtenberg, J. Zijlstra, 2006, Critical care.

Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.

E. Giovannetti, G. Peters, E. Smit, 2012, Current pharmaceutical design.

Response and toxicity prediction by MALDI‐TOF‐MS serum peptide profiling in patients with non‐small cell lung cancer

E. Smit, H. Verheul, T. Pham, 2016, Proteomics. Clinical applications.

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.

E. Smit, P. Postmus, E. Thunnissen, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.

E. Smit, S. Senan, F. Lagerwaard, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.

E. Smit, S. Senan, F. Lagerwaard, 2009, International journal of radiation oncology, biology, physics.

Time for reappraisal of extracranial treatment options?

E. Smit, P. Postmus, S. Senan, 2011, Cancer.